Characteristic Placebo (n = 31) Betahistine (n = 31) Total (n = 62)
Age, median (IQR), y 54 (48 to 60) 56 (47 to 64) 54 (48 to 60)
Sex, no. (%)
Males
15 (48.39)
17 (54.84)
32 (51.61)
Females
16 (51.61)
14 (45.16)
30 (48.39)
Race, no. (%)
White
27 (87.10)
30 (96.77)
57 (91.94)
Black
1 (3.23)
0 (0)
1 (1.61)
Others
3 (9.68)
1 (3.23)
4 (6.45)
Educational level, no. (%)
Primary incomplete
4 (12.9)
6 (19.35)
10 (16.13)
Primary
0 (0)
2 (6.45)
2 (3.23)
Secondary incomplete
0 (0)
4 (12.9)
4 (6.45)
Secondary
14 (45.16)
13 (41.94)
27 (43.55)
Tertiary
13 (41.94)
6 (19.35)
19 (30.65)
Guardian help to fill the THI score, no. (%) 5 (16.13) 9 (29.03) 14 (22.58)
Mild Hearing loss, no. (%) 24 (77.42) 21 (67.74) 45 (72.58)
Occupational noise, no. (%) 3 (9.67) 3 (9.67) 6 (9.67)
Diabetes mellitus, no. (%) 3 (9.68) 3 (9.68) 6 (9.68)
Psychiatric illness, no. (%) 8 (25.81) 4 (12.9) 12 (19.35)
Migraine, no. (%) 5 (16.13) 5 (16.13) 10 (16.13)
Tinnitus duration, median (IQR), y 6 (3 to 10) 5 (2 to 8) 5 (2 to 10)
THI, median (IQR) 44 (30 to 68) 44 (28 to 62) 44 (30 to 66)